Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 study of hMaxi-K as a treatment for OAB patients who have not responded to other pharmacological therapies

Trial Profile

A Phase 2 study of hMaxi-K as a treatment for OAB patients who have not responded to other pharmacological therapies

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs Maxi-K gene therapy (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2018 New trial record
    • 28 Aug 2018 According to an Urovant Sciences media release, the company plans to meet with the FDA to initiate the study in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top